Macrophage homeostasis implies proper function for its specific tissue, environment and challenge
Reprogramming imbalanced macrophage populations can lead to disease resolution
Macrophages’ function is a sum of their designation, the local environment in which they reside, and the type of situation or pathogen to which they are exposed. Reprogrammed out of their homeostatic state, macrophages contribute to the pathophysiology of multiple diseases including cancer and various inflammatory disorders.
We reset macrophages into their homeostatic state
Pipeline of reprogrammable macrophage-modulated indications
| Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
Potential support for EU Conditional Marketing Approval Submission |
Post EU Marketing US Phase 3 |
|
|---|---|---|---|---|---|---|---|
| Organ failure associated with Sepsis | $33B | Completed | Randomized, controlled Phase II ongoing |
Top-line data for Phase II Q1-24 | |||
| Moderate knee osteoarthritis | $7B | Phase I/II ongoing |
Randomized, controlled Phase I/II expected Q1 2024 |
Top-line data for Phase I/II Q2-25 | |||
| End-stage knee osteoarthritis $2B Phase I/II | $2B | Phase I/II ongoing |
Top-line data for Phase I/II Q2-24 | ||||
Our Mission
Our mission is to establish new equilibriums that solve complex diseases.
As a clinical-stage company focused on macrophage reprogramming, we intend to develop and commercialize a drug pipeline for macrophage reprogramming in Sepsis, Osteoarthritis, solid cancers, COVID-19 and other indications.
Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.